AVBP
ArriVent BioPharma, Inc.
$29.50
+2.25%
2026-05-08
About ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Key Fundamentals
Forward P/E
-9.06
EPS (TTM)
$-4.32
ROE
-58.9%
Profit Margin
0.0%
Debt/Equity
0.01
Price/Book
3.99
Beta
1.52
Market Cap
$1.34B
Avg Volume (10D)
462K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$32.14
60D Low
$20.73
Avg Volume
479K
Latest Close
$29.50
Get breakout alerts for AVBP
Sign up for Breakout Scanner to receive daily notifications when AVBP triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
ArriVent BioPharma, Inc. (AVBP) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AVBP daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AVBP operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.